Literature DB >> 15769628

Microdialysis - an in vivo technique for studies of growth factors in breast cancer.

Charlotta Dabrosin1.   

Abstract

Changes in the microenvironment are important in the development of cancer and further tumor growth. Although landmark discoveries have been made regarding genetic alterations in cancer at a cellular level very little is known about protein regulation in the extracellular space. In the microenvironment many growth factors are activated at a post-translational level by interactions of different cell types such as epithelial cells, fibroblasts, adipose cells, and immune cells. The extracellular space is the bioactive site for the majority of growth factors and increased knowledge of protein activation in this compartment is of utmost importance for our comprehension of tumor biology. Microdialysis is a minimally invasive technique, which enables sampling of molecules in the extracellular space. It is applicable in human cancer as well as in experimental tumors. This review describes microdialysis, its application and the up to date literature of microdialysis for detection of growth factors in cancer with special emphasis on breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769628     DOI: 10.2741/1622

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  14 in total

1.  Dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironment in vivo.

Authors:  Annelie Abrahamsson; Anna Rzepecka; Thobias Romu; Magnus Borga; Olof Dahlqvist Leinhard; Peter Lundberg; Johan Kihlberg; Charlotta Dabrosin
Journal:  Oncoimmunology       Date:  2016-09-02       Impact factor: 8.110

2.  Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ.

Authors:  Peter Lundberg; Mikael F Forsgren; Jens Tellman; Johan Kihlberg; Anna Rzepecka; Charlotta Dabrosin
Journal:  Br J Cancer       Date:  2022-09-22       Impact factor: 9.075

Review 3.  In vivo tumor secretion probing via ultrafiltration and tissue chamber: implication for anti-cancer drugs targeting secretome.

Authors:  Chun-Ming Huang; Teruaki Nakatsuji; Yu-Tseung Liu; Yang Shi
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-01       Impact factor: 4.169

4.  Interstitial fluid: the overlooked component of the tumor microenvironment?

Authors:  Helge Wiig; Olav Tenstad; Per Ole Iversen; Raghu Kalluri; Rolf Bjerkvig
Journal:  Fibrogenesis Tissue Repair       Date:  2010-07-23

Review 5.  Breast tumor microenvironment: proteomics highlights the treatments targeting secretome.

Authors:  Shui-Tein Chen; Tai-Long Pan; Hsueh-Fen Juan; Tai-Yuan Chen; Yih-Shyan Lin; Chun-Ming Huang
Journal:  J Proteome Res       Date:  2008-02-22       Impact factor: 4.466

6.  Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer.

Authors:  Karin Söderlund Leifler; Susanne Svensson; Annelie Abrahamsson; Christina Bendrik; Jennifer Robertson; Jack Gauldie; Anna-Karin Olsson; Charlotta Dabrosin
Journal:  J Immunol       Date:  2013-03-15       Impact factor: 5.422

7.  Dietary flaxseed and tamoxifen affect the inflammatory microenvironment in vivo in normal human breast tissue of postmenopausal women.

Authors:  Gabriel Lindahl; Annelie Abrahamsson; Charlotta Dabrosin
Journal:  Eur J Clin Nutr       Date:  2019-01-28       Impact factor: 4.016

8.  Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo.

Authors:  Ulrika W Nilsson Åberg; Niina Saarinen; Annelie Abrahamsson; Tarja Nurmi; Sofia Engblom; Charlotta Dabrosin
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

9.  In vivo measurement of tumor estradiol and vascular endothelial growth factor in breast cancer patients.

Authors:  Stina Garvin; Charlotta Dabrosin
Journal:  BMC Cancer       Date:  2008-03-18       Impact factor: 4.430

Review 10.  Tumor Interstitial Fluid Formation, Characterization, and Clinical Implications.

Authors:  Marek Wagner; Helge Wiig
Journal:  Front Oncol       Date:  2015-05-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.